CFM
CASI

Catalyst Funds Management’s CASI Pharmaceuticals CASI Stock Holding History

Catalyst Funds Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8
Closed -$44 – 1332
2024
Q2 		$44 Sell
8
-1,802
-100% -$5.6K ﹤0.01% 1138
2024
Q1 		$6.53K Buy
+1,810
New +$9.75K ﹤0.01% 952

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Catalyst Funds Management's CASI Position: Q3 2024 in Review

Catalyst Funds Management sold out of CASI Pharmaceuticals (CASI) in Q3 2024, closing a stake of 8 shares — an estimated $44 sold.

Catalyst Funds Management first reported a position in CASI in Q1 2024 and held it in 2 quarters. The position peaked at $6.53K in Q1 2024. 20 funds tracked by Wall St. Rank hold CASI as of Q3 2024.

  • Catalyst Funds Management reported no remaining CASI Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 8 CASI Pharmaceuticals shares in Q3 2024, an estimated $44.
  • Catalyst Funds Management first reported a position in CASI Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's CASI Pharmaceuticals position peaked at $6.53K in Q1 2024.
  • 20 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.